References
- Wu ML, Aziz DB, Dartois V, et al. NTM drug discovery: status, gaps and the way forward. Drug Discov Today. 2018;23(8):1502–1519.
- Izumi K, Morimoto K, Hasegawa N, et al. Epidemiology of adults and children treated for nontuberculous mycobacterial pulmonary disease in Japan. Ann Am Thorac Soc. 2019;16(3):341–347.
- Wallace RJ Jr., Brown-Elliott BA, McNulty S, et al. Macrolide/azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. Chest. 2014;146(2):276–282.
- Lee BY, Kim S, Hong Y, et al. Risk factors for recurrence after successful treatment of mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2015;59(6):2972–2977.
- Asakura T, Nakagawa T, Suzuki S, et al. Efficacy and safety of intermittent maintenance therapy after successful treatment of mycobacterium avium complex lung disease. J Infect Chemother. 2019;25(3):218–221.
- Martiniano SL, Wagner BD, Levin A, et al. Safety and effectiveness of clofazimine for primary and refractory nontuberculous mycobacterial infection. Chest. 2017;152(4):800–809.
- Philley JV, Wallace RJ, Benwill JL, et al. Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease. Chest. 2015;148(2):499–506.
- Choi SW, Gu YX, Peters RS, et al. Ambroxol induces autophagy and potentiates rifampin antimycobacterial activity. Antimicrob Agents Chemother. 2018;62(9).
- Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273–286.
- Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant mycobacterium abscessus. Nat Med. 2019;25(5):730–+.